A randomized, open-label, parallel, controlled study of Wulingshen in the treatment of poststroke fatigue

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001629

Enrollment

Unknown

Registered

2011-10-23

Start date

2011-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

treatment group:Wulingshen Capsule (produced by Zhejing Jolly Pharmaceutical Co., Ltd) 0.99g (3 capsules), tds, orally, for 12 weeks, together with standard medications for secondary prevention of isc

control group:Vitamin C tablets 0.1g (1 tablet), tds, orally, for 12 weeks, together with standard medications for secondary prevention of ischemic stroke according to the Chinese stroke guideline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) aged between 40 to 85 years; (2) had a history of ischemic stroke confirmed by CT or MRI 1-6months before; (3) were willing and able to give informed consent; (4) had a average Fatigue Severity Score (FSS) >=4.0.

Exclusion criteria

Exclusion criteria: (1) modified Rankin Scale>=3; (2) schizophrenia or dementia; (3) had significant aphasia or dysarthria; (4) Major depression (DSM-IV criteria).

Design outcomes

Primary

Measure	Time frame
Score of Fatigue Severity Scale (FSS);	—

Secondary

Measure	Time frame
Score of Stroke-Specific Quality of Life (SS-QOL);Scores of Hamilton Depression Scale and Hamilton Anxiety Scale;	—

Countries

China

Contacts

Public ContactYangkun Chen

davischan78@gmail.com+86 13713135765

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026